Madrigal Pharmaceuticals, Inc.
MDGL NASDAQHealthcare ★★★★★Latest Earnings Above forecast↑
Date
Jul 30, 2026
ET
EPS Est.
-2.68
EPS Actual
-1.99
Revenue Est.
$352.1M
Revenue Actual
$364.3M
Next Earnings Report
Date
Nov 3, 2026 · Tue
Time
Pre-market
Fiscal Period
FY2026 Q3
EPS Est.
-0.86
Revenue Est.
$404.2M
Company Overview
Madrigal Pharmaceuticals, Inc. (ticker MDGL) is listed on NASDAQ with a market cap of about $11.94B. Its next earnings report (FY2026 Q3) is expected on Nov 3, 2026 (ET), Pre-market, with consensus EPS of -0.86. In the last 15 reported quarters, EPS beat consensus estimates 8 times.
Actual EPS TrendRecently15Term · Feb 23, 2023 → Jul 30, 2026
Feb 23, 2023Range: -7.38 ~ -1.90Jul 30, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 30, 2026 | -- | -2.68 | Above forecast↑-1.99 | $352.1M | $364.3M |
| May 6, 2026 | -- | -3.61 | -3.25 | $301.1M | $311.3M |
| Feb 19, 2026 | -- | 0.04 | Below forecast↓-2.57 | $312.5M | $321.1M |
| Nov 4, 2025 | -- | -2.04 | Below forecast↓-5.08 | $245M | $287.3M |
| Aug 5, 2025 | -- | -3.48 | Above forecast↑-1.90 | $243.5M | $212.8M |
| May 1, 2025 | -- | -3.62 | -3.32 | $158.9M | $137.3M |
| Feb 26, 2025 | -- | -4.32 | Above forecast↑-2.71 | $97.8M | $103.3M |
| Oct 31, 2024 | -- | -6.94 | Above forecast↑-4.92 | $92.5M | $62.2M |
| Aug 7, 2024 | -- | -7.55 | -7.10 | $3.9M | $14.6M |
| May 7, 2024 | -- | -6.06 | Below forecast↓-7.38 | $3.9M | -- |
| Feb 28, 2024 | -- | -5.32 | -5.68 | -- | $770000 |
| Nov 6, 2023 | -- | -4.78 | -5.34 | -- | -- |
| Aug 8, 2023 | -- | -4.47 | -4.69 | -- | -- |
| May 9, 2023 | -- | -4.98 | Above forecast↑-4.23 | -- | -- |
| Feb 23, 2023 | -- | -4.41 | -4.98 | -- | -- |
Original Filings (SEC)
8-K2026-08-12 ↗
10-Q2026-07-30 ↗
8-K2026-07-30 ↗
8-K2026-06-17 ↗
10-Q2026-05-06 ↗
8-K2026-05-06 ↗
8-K2026-04-28 ↗
10-K2026-02-19 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
